The number of stroke cases among adults and children with sickle cell disease (SCD) continues to increase in at least one U.S. state, indicating a need for greater adherence to standard-of-care blood transfusions and more attention paid to factors that can be controlled to reduce the risk of…
A $1.9-million federal grant has been awarded to a clinical trial that seeks to find effective ways to improve adherence to hydroxyurea treatment among children and young adults with sickle cell disease (SCD). Marketed as Droxia and Siklos, hydroxyurea is an oral therapy approved to reduce the frequency…
People with sickle cell disease (SCD) treated with hydroxyurea in the U.S. still face many challenges, including the financial burden posed by their healthcare expenses, low treatment adherence and high treatment discontinuation rates, according to a study based on pharmacy claims data. The study, “Treatment patterns and…
Get regular updates to your inbox.